RNA viruses frequently bypass the conventional 5′ cap‐dependent mechanism of translation by employing alternative strategies that enable them to commandeer the host’s translational machinery. A ...

The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The ...

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...

The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The influenza virus continues to pose a threat to our health. It triggers seasonal ...

Under the agreement, Quantoom will have access to TriLink’s CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...